Publication

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its…

New paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyzing complex regions of the human pangenome Recently released human pangenome better…

SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing…

PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet…

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support…

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of its Phase 1/2…

-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older…

Technology leverages new coating process to create 3D scaffold matrix that is designed to mimic the tumor microenvironment and enable large scale tumor cell expansionDemonstrated successful…

ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the…

AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients…